ABSTRACT
OBJECTIVE: To determine whether postmarketing data provide evidence of an association of sibutramine with bruising. DESIGN AND PATIENTS: During a postmarketing surveillance study of sibutramine in New Zealand by the Intensive Medicines Monitoring Programme (IMMP), a series of reports of bruising was identified. Further case reports were also obtained from the World Health Organisation (WHO) adverse drug reactions database. OUTCOME MEASURES: All platelet, bleeding and clotting events associated with sibutramine were identified and causality assessments were performed. RESULTS: From the IMMP and WHO databases a total of 16 cases of bruising that improved on withdrawal of sibutramine were identified. Of these, two had a recurrence of bruising on reintroduction of sibutramine. CONCLUSIONS: Evidence from postmarketing surveillance suggests that there is a causal association between sibutramine and bruising/ecchymosis. This represents a newly recognized adverse reaction for this medicine.
